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Background: Vaccination is a complex ecosystem with several components that interact with one another and
with the environment. Today’s vaccine ecosystem is defined by the pursuit of polio eradication, the drive to get as
many of the new vaccines to as many people as possible and the research and development against immunologically
challenging diseases. Despite these successes, vaccine ecosystem is facing keys issues with regard to supply/distribution
and cost/profitability asymmetry that risk slowing its global growth.
The conference “Vaccination ecosystem health check: achieving impact today and sustainability for tomorrow” held in
Annecy-France (January 19–21, 2015) took stock of the health of today’s vaccination ecosystem and its ability to reliably
and sustainably supply high-quality vaccines while investing in tomorrow’s needed innovation.
Main findings: Small and decreasing numbers of suppliers/manufacturing facilities; paucity of research-driven companies;
regulatory pressures; market uncertainties; political prioritization; anti-vaccine movements/complacency; and technological
and programmatic issues were acknowledged as the major challenges that could weaken today’s vaccination ecosystem.
The expert panel discussed also drivers and barriers to a sustainable vaccination ecosystem; the metrics of a vaccination
ecosystem; and what should be added, removed, increased, or reduced to maintain the health of the vaccination
ecosystem.
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Vaccination comprises a complex ecosystem similar to
natural ecosystems; it can be represented as an organism-
community of international organizations, vaccine manu-
facturers, donor agencies, foundations, nongovernmental
organisms, etc. that interact with one another and with
the environment. As a consequence, modifications or vari-
ations in one of its components can affect the ecosystem
balance.
National immunization programs together with Gavi, the
Vaccine Alliance (Gavi), international aid, philanthropic
donors, tiered pricing by large research and development* Correspondence: mitra.elahi@chu-lyon.fr
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eric vaccines have significantly decreased vaccine access
gaps between high- and low-income countries by improv-
ing vaccination of the world’s poorest children. However,
this success should not prevent continuous examination of
whether we are fully optimizing the huge untapped poten-
tial of today’s vaccines without damaging the benefit that
future vaccination innovation can bring.
Today’s vaccine ecosystem is defined by the pursuit of
polio eradication, the drive to get as many of the new
vaccines to as many people as possible and the R&D
pursuit of vaccines against immunologically challenging
diseases such as HIV, Malaria, TB, Dengue, RSV, HSV,
Chlamydia and others. This era is also characterized by
the emergence of major private donors and governmentle is distributed under the terms of the Creative Commons Attribution 4.0
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global access to all vaccines through «push and pull»
innovation in vaccines and vaccines systems. To achieve
this they implement “market-shaping” aimed at incentiv-
izing increased volumes, lower prices and new producers
of high volume, low-cost versions of existing vaccines.
To take stock of the health of today’s vaccination eco-
system and its ability to reliably and sustainably supply
high-quality vaccines while investing in tomorrow’s
needed innovation, Fondation Mérieux organized a con-
ference entitled “Vaccination ecosystem health check:
achieving impact today and sustainability for tomor-
row” on January 19–21, 2015, in Annecy, France. Par-
ticipants included representatives from international
organizations [WHO, Gavi, international facility for the
purchase of drugs against HIV/AIDS, Malaria and
Tuberculosis (UNITAID), Médecins Sans Frontières
(MSF), etc.] and industry.
To elicit more consideration of the vaccine ecosystem,
a breakout session was held for participants in small
working groups to discuss how to keep the vaccination
ecosystem healthy.
This report summarizes selected issues discussed by
participants, including the key findings and recom-
mendations for future approaches to addressing this
issue.Fig. 1 Vaccine ecosystem, a simplified model [1]Vaccination ecosystem
The vaccine ecosystem involves a large number of actors
(producers, purchasers, payers, supply side facilitators,
program implementers, etc.) with mutual interactions
(Fig. 1) [1]. Vaccine producers are conventionally divided
into two groups: those investing large parts of their reve-
nues in research and development (R&D) and those pri-
marily involved in manufacturing and sales. The first
group mainly consists of multinational firms based in
the United States and Europe, even if emerging manu-
facturers from developing countries are scaling up. Gov-
ernments, philanthropic organizations, WHO, and Gavi
ensure vaccine purchasing, while the United Nations
Children’s Fund (UNICEF) is the global lead for vaccine
procurement.
The Gavi Alliance mainly ensures access to immunization
in poor countries. Currently, Gavi supports routine vaccin-
ation programs (pentavalent, pneumococcal, yellow fever,
etc.), vaccination campaigns (yellow fever, Meningococcal
A, measles-rubella, Japanese encephalitis), stockpile for
outbreak responses (yellow fever, meningitis, cholera) and
malaria vaccine pilot, supply and procurement strategy.
UNICEF works in partnership with governments, global
partners, and a large number of suppliers. The continuous
changes in both supply and demand creates a dynamic
market that requires continuous monitoring and
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increased significantly since 2000 due to the introduction of
new vaccines. In 2014, UNICEF procured 2.70 billion doses
of more than 40 vaccines for 100 countries at a value of
$1.474 billion. Currently, the largest contributions come
from industrialized countries, but emerging markets’ par-
ticipation is increasing over time.
The participants attempted to analyze the health of
vaccine eco-system in terms of coverage, demand,
supply, and R&D.
Global vaccine coverage, demand, and supply
The establishment of the World Health Organization
Expanded Program on Immunization (WHO-EPI) more
than 40 years ago, adequate program design and imple-
mentation and international cooperation have led not
only to increased vaccine coverage rates around the
world, but also to reduced disease burden [2–4], and to
smaller access inequities between low- and high-income
countries even for new vaccines such as hepatitis B and
pneumococcal vaccines. Despite these successes, large
coverage gaps remain, which will need significant finan-
cial resources and political motivations to address.
Indeed, the limited number of manufacturers and buyers
in parallel to an increasing demand in terms of new vac-
cines introduced in the WHO-EPI especially in lower-
income countries, could create a disconnect between
demand and supply.
An important unaddressed challenge is to vaccinate
the 20% of the world’s children born each year that do
not receive even the most basic vaccinations. In 2011,
the Global Vaccine Action Plan (GVAP) for the Decade
of Vaccines (DoV) was created with the ambitions to
close the equity gap in vaccine delivery and to unleash
vaccines’ vast future potential. The new global vaccines
and immunization framework provides space for all
stakeholders to improve delivery, demand, and research.
GVAP mid-point targets were 1) Diphtheria-Pertussis-
Tetanus (DTP3) coverage >90% in all countries and
>80% in every district by 2015, 2) polio transmission
stopped by 2014, 3) maternal and neonatal tetanus elimi-
nated by 2015, 4) measles eliminated in four regions by
the end of 2015, 5) rubella eliminated in two regions by
the end of 2015, and 6) introduction of one or more
underutilized vaccines in low- or middle-income countries
by 2015. An independent assessment performed by the
Strategic Advisory Group of Experts on Immunization
(SAGE) in 2014 expressed concerns about low imple-
mentation of GVAP as all targets except the last one
were off track.
Global vaccine research and development
The vaccine industry is entering a period of uncertainty
that threatens the new vaccine pipeline. Additionalneeds for basic science research; continuously rising
manufacturing standards and regulatory requirements;
the scientific challenge of developing vaccines for unmet
needs (cytomegalovirus, HIV, tuberculosis, etc.); and
increased cost, time, and risk of vaccine research and de-
velopment driven by late-stage (phase 3) trials are
among major contributing factors that limit the number
of vaccines that a company is willing or able to develop
to meet public health needs. One important result of this
situation is that major companies are only interested in
blockbusters. Therefore, main vaccine manufacturers do
not consider many infections with somewhat restricted
market size such as Lyme, cryptosporidium, and West
Nile a top priority. Furthermore, the pressure to keep
vaccine prices low, both in developed and developing
countries, threatens to move manufacturing capability
out of North America and Europe to reduce costs.
Today’s vaccination ecosystem health status
Today’s vaccine ecosystem is facing keys issues with re-
gard to supply/distribution and cost/profitability asym-
metry that risk slowing the global health of vaccine
ecosystem. Indeed, a disconnect exists between the
WHO global vaccine action plan (GVAP) and market
shaping This could be due to overdependence on “price
reduction” metrics and underdeveloped metrics for fu-
ture innovation and supply security. Furthermore, cost/
profitability asymmetries could provoke market exit and
market failure when reinvestment is required. Several
years of yellow fever vaccine shortage illustrates this
situation well [5, 6]. New challenges related to popula-
tion growth; increase in the number, doses, and cost of
vaccines targeting a wider age group beyond that of in-
fants; inadequate systems (trained human resources,
supply chain, information system); vaccine supply and
price (i.e., availability, financing, pricing, and procure-
ment); and the goal of reaching the 20% of the world’s
children born each year that are never (or incompletely)
vaccinated due to political crisis, migration, failure of
integration (i.e., missed opportunities), hesitancy, and
refusal, further amplify the complexity of the vaccin-
ation ecosystem.
Possible solution frameworks
Possible solutions discussed during the conference for
sustaining a healthy vaccination ecosystem are summa-
rized in the following paragraphs.
Global vaccine coverage, demand, and supply
High-quality data are crucial to empower immunization
program management, to increase vaccine uptake and to
reach those children who are never vaccinated. Regular
data review, data triangulation with other available
sources, periodic data quality assessment, and training of
Table 1 Risk of intussusception following rotavirus vaccination
Vaccine Phase III Clinical Trial Post introduction
Rotateq RR = 1.6 (95% CI: 0.4–6.4) [10] RR = 9.9 (95% CI: 3.7–26.4) [11]
Rotarix RR = 0.86 (p = ns) [12] RR = 6.8 (95% CI:2.4–19.0) [11]
RR Relative risk, CI Confidence interval, ns not statistically significant
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considerably improve data quality. Household surveys to
measure immunization coverage are also needed to val-
idate administrative data and provide additional infor-
mation on missed opportunities and timely vaccination.
Using traditional methods such as home-based vaccin-
ation records and new technologies such as modern
Information, Communication and Technology (ICT)
tools can also considerably improve data quality and
thus contribute to improvement in coverage.
Another issue that can influence global vaccine cover-
age concerns the sustainability of financial support for
Gavi–eligible graduating countries. Price-freezing for a
period of five years is a possible solution, currently
under evaluation, for these countries to sustain their ex-
panded immunization programs without facing huge
economic impact.
Weak immunization supply chain systems are another
bottleneck to achieving immunization goals. Fortunately,
key supply chain challenges have been diagnosed and
their importance acknowledged. New technologies to re-
duce storage volume, expand the reach of cold chain to
areas without reliable energy sources using solar equip-
ment or long-lasting vaccine containers, provide new
vaccine delivery models, allow combined vaccines and
better schedules (number or timing of doses) are some
technical solutions that exist and/or are in development
and that could address vaccine supply challenges.
As described previously, the existing disconnects be-
tween demand and supplies are due to the limited num-
ber of manufacturers and buyers and the increasing
demand in terms of vaccine products. Gavi adopted a
supply and procurement strategic goal to shape the vac-
cine market by balancing supply and demand, ensuring
security of supply, minimizing the cost of vaccines, and
fostering development of appropriate and quality
vaccines. So far, Gavi increased the number of vaccine
suppliers from five in 2001 to 15 in 2014, including
manufacturers from emerging markets. Other procure-
ment strategies could further improve vaccine supply,
including negotiation such as selective contracting/ex-
clusive dealing and auctions.
Global vaccine research and development
Possible solutions for sustaining vaccine research and
development and innovation are 1) incentives for indus-
try to invest in new vaccines and improve old vaccines,
2) agreement between Food and drug administration/
European medicine agency (FDA/EMA) to limit num-
bers needed for efficacy trials (phase 2B versus phase 3
trials), 3) increased interaction between high- and low-
income countries to facilitate technology transfer, and 4)
set-up of an international vaccine development fund that
would support biotech escalating from lab to proof ofconcept and vaccine manufacturers developing vaccines
for tropical and neglected diseases. Policies that make
innovation and distribution reasonably profitable could
also address these issues. Such policies include providing
government supports for development and production,
reducing uncertainty by establishing clear property
rights, taxing negative spillovers, and subsidizing positive
spillovers. Innovation must be profitable, but regulation
to lower prices can slow innovation and diffusion by re-
ducing return on investment. A price that is affordable
to governments and donors and reasonably covers man-
ufacturer’s minimum requirement could thus enhance
vaccine R&D. Price discrimination, i.e., different prices
for the same product in different settings (e.g., developed
vs. developing countries), could also allow profitability
to be maintained, thus generating more innovation. In
low-income countries, differential patent rights, compul-
sory licenses, prizes, and advance market commitments
to recommend a vaccine once licensed could also ad-
dress supply and innovation.
Conditional licensure of vaccines as part of a system
that would incorporate a requirement for rapid cycle
and other real-time evaluations following introduction is
another potential solution. Indeed, the cost and time of
large routine safety trials prior to vaccine licensure are
constantly increasing and could have a negative impact
on the vaccine development pipeline without concomi-
tant and dramatic increase in our ability to assess safety.
The examples of Rotateq and Rotarix show that despite
very large phase 3 clinical trials, increased risk of intus-
susception only became apparent and statistically signifi-
cant in the post licensure period (Table 1).
Similarly, post-introduction data on pneumococcal con-
jugated vaccines (PCV) show that the vaccine had higher
impact on the reduction of invasive pneumococcal
diseases, otitis media, and all causes of pneumonia than
what was reported in phase III clinical trials (Table 2).
Conditional licensure will lower the financial barriers
to development of new vaccines and consequently allow
a broader portfolio of vaccines to be developed.
Valuing vaccination
In recent years, a compelling line of inquiry has estab-
lished the economic benefits of health, at both individual
and aggregate levels. Most economic evaluations of
vaccines focus on a narrow set of vaccination-mediated
benefits (i.e., avoided medical costs and absenteeism)
and fail to account for the role of vaccination as a driver
Table 2 Comparison of phase III clinical trials and post
marketing data on PCV efficacy
Outcome Phase III Clinical Trial Post introduction
IPD 93.9% (95% CI: 79.6–98.5) [13] >99% [14]
Otitis media 7.0% (95% CI: 4.1–9.7) [13] 20% (95% CI: 4–34) [15]
All cause pneumonia
(<5Y)
6% (95% CI:-1.5–11) [16] 39% (95% CI: 22–52) [17]
Cost-effectiveness US$80,000/QALY [18] US$75,000/QALY [19]
IPD Invasive pneumococcal diseases, CI Confidence interval, QALY Quality-
adjusted life year
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tentially sizable undervaluation of the true economic
value of vaccines. A broader perspective in economic
analysis considers other benefit categories including 1)
outcome-related productivity gains, 2) behavior-related
productivity gains, 3) community externalities (i.e., herd
effect and prevention of antibiotic resistance), and 4)
utilitarian value of health gains. Cost-effectiveness and
benefit-cost analyses are tools to assess the value of vac-
cination. The latter is more appropriate for economic
analysis because it looks at a range of health and non-
health related outcomes that are expressed in terms of a
dollar value. The example of Hib vaccine in children
provided evidence of a benefit-cost ratio above 1 [7].
Another example is the case of dengue infection. By tak-
ing into account reduced spending on outbreak control,
averted losses in tourism flows, and avoided productivity
losses due to long-term dengue sequel, introducing den-
gue vaccine in national immunization programs in Brazil
would more than double the narrow benefit calculation,
allowing twofold return on the investment [8]. Similar
conclusions can be drawn for human papilloma virus
(HPV) vaccination if the full benefits of vaccination are
captured [9].
Conceptualizing the full benefits of vaccination allows
better recognition of the value of vaccination as a driver
of both wealth and health. Monetizing the impact of
vaccination provides policymakers with sufficient infor-
mation to make well-informed decisions about including
other new vaccines in national immunization programs.
Outcomes of the workshops
Breakout sessions following the overall presentations on
the current status of today’s vaccination ecosystem
allowed participants to discuss main topics that deserved
more in-depth attention.
Different factors were identified as drivers or barriers
that could influence the sustainability of the vaccine eco-
system in terms of vaccine coverage, supply and demand
as well as R&D (Additional file 1). The working group
identified also several items to improve or add to ensure
the health of the vaccination ecosystem (Additional file 2).
Furthermore, reduction of the precautionary principle ingovernment regulation and market failure could also con-
tribute to the health of the vaccination ecosystem.
Conclusions and recommendations
The panel concluded that despite the considerable pro-
gress achieved, introduction of new vaccines in LMICs,
sustained coverage with new and traditional vaccines,
and better performance of supply chains), today’s vaccin-
ation ecosystem faces several challenges that could
weaken it. These include small and decreasing numbers
of suppliers/manufacturing facilities; paucity of research-
driven companies; regulatory pressures; market un-
certainties (cost-effectiveness, price, higher demand and
supply); political prioritization (competing priorities or
distortion due to crisis, political instability); anti-vaccine
movements/complacency; and technological and pro-
grammatic issues (supply chain, cold chain custody,
health care worker education).
However, the panel identified several potential solutions.
Guaranteed return on investment for donors, govern-
ments, and global stakeholders; presence of multiple
effective suppliers to reduce monopolies and secure sup-
ply; financing for research and development; political
prioritization by raising awareness about needs; empower-
ment of developing country manufacturers (e.g., technol-
ogy transfer); and balance of public-private perspectives
for global public goods and distinction of the roles of each
sector could positively affect the vaccination ecosystem.
In parallel, the current low-price-focused market shaping
could lead to critical asymmetry between cost and profit-
ability for Gavi–dedicated vaccines. This phenomenon is
apparent in the supply shortage for most Gavi vaccines,
exit of R&D producers from production to heritage vac-
cines, increased concentration of most vaccine production
by fewer producers, increased number of vaccines with just
one or two suppliers, and static or falling levels of vaccine
producers and R&D activity. Challenging vaccine prices is
complex. The need exists to collect more accurate data to
assess the full benefits of vaccines because we cannot chal-
lenge the cost without considering the whole benefits.
Piggyback analysis, i.e., economic evaluation embedded in
clinical trials, would be a good way to quantify economic
values of vaccines in terms of productivity, for example.
However, this would need expensive long-term follow-up.
To summarize, the concept of an ecosystem is a useful
way of thinking about vaccines. A healthy ecosystem
should be able to maintain its organization and function
over time in the face of external stress. The supply issue
is a central aspect that requires much more work. Re-
search and development also face challenges. Prioritizing
a list of vaccine-preventable diseases to target and
matching it with R&D activities could optimize the lat-
ter, especially if a global development fund is in place.
Mechanisms such as regulatory reforms and technical
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disruption periods could also contribute to the sustain-
ability of the vaccination ecosystem. Our goal should be
to investigate how we can best work together to ensure
the sustainability of increasing global vaccination with-
out damaging global vaccine production and/or R&D. A
shared responsibility is needed to keep the vaccination
ecosystem healthy.Additional files
Additional file 1: Drivers and barriers to a sustainable vaccination
ecosystem. (DOCX 17 kb)
Additional file 2: Requirements for a healthier vaccination ecosystem.
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